APA (7th ed.) Citation

Crestani, B., & Kreuter, M. (2019). Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. The lancet. Respiratory medicine, 7(1), . https://doi.org/10.1016/S2213-2600(18)30339-4

Chicago Style (17th ed.) Citation

Crestani, Bruno, and Michael Kreuter. "Long-term Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Results from the Open-label Extension Study, INPULSIS-ON." The Lancet. Respiratory Medicine 7, no. 1 (2019). https://doi.org/10.1016/S2213-2600(18)30339-4.

MLA (9th ed.) Citation

Crestani, Bruno, and Michael Kreuter. "Long-term Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Results from the Open-label Extension Study, INPULSIS-ON." The Lancet. Respiratory Medicine, vol. 7, no. 1, 2019, https://doi.org/10.1016/S2213-2600(18)30339-4.